Literature DB >> 3195996

In vitro activity of DR-3355, an optically active ofloxacin.

T Une1, T Fujimoto, K Sato, Y Osada.   

Abstract

DR-3355, the S-(-)-isomer of ofloxacin, was generally twice as potent as ofloxacin against a variety of gram-positive and gram-negative pathogens, and its action was bactericidal. The compound was characterized by having the highest level of activity against staphylococci, Bacteroides fragilis, and Peptococcus spp. of the fluorinated quinolones tested, including ofloxacin, ciprofloxacin, fleroxacin, and NY-198. The activity of DR-3355 was not affected by different media, inoculum size, or human serum, but decreased under acidic conditions at pH 5.0 or in human urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3195996      PMCID: PMC175863          DOI: 10.1128/AAC.32.9.1336

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors:  J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Inhibition of DNA gyrase by optically active ofloxacin.

Authors:  M Imamura; S Shibamura; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

5.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

6.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors.

Authors:  P C Taylor; F D Schoenknecht; J C Sherris; E C Linner
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H- benzo[ij]quinolizine-2-carboxylic acid.

Authors:  J F Gerster; S R Rohlfing; S E Pecore; R M Winandy; R M Stern; J E Landmesser; R A Olsen; W B Gleason
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

10.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  42 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Authors:  S C Chien; A T Chow; M C Rogge; R R Williams; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.

Authors:  S Yoshizumi; H Domon; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

9.  Characterization and its potential application of two esterases derived from the arctic sediment metagenome.

Authors:  Jeong Ho Jeon; Jun-Tae Kim; Sung Gyun Kang; Jung-Hyun Lee; Sang-Jin Kim
Journal:  Mar Biotechnol (NY)       Date:  2008-09-24       Impact factor: 3.619

10.  Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections.

Authors:  Yoshiko Kanda; Tomoko Kayama; Shinji Okamoto; Masako Hashimoto; Chiemi Ishida; Tomoko Yanai; Mitsuru Fukumoto; Eiichi Kunihiro
Journal:  Drugs R D       Date:  2012-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.